Physician profile

Sushma Singh

Infectious Disease · Sugar Land, TX

NPI 1245493360

$1,596.18

in general payments reported to CMS, 2019-2025

20 companies · none reported in 2025

See the full distribution for Infectious Disease

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Merck Sharp & Dohme LLC $256.71 2019-2022
Paratek Pharmaceuticals, INC. $202.53 2020-2022
Astellas Pharma US INC $200.57 2019
Abbvie INC. $150.02 2021-2022
Insmed, INC. $150.01 2019-2022
Shionogi INC $134.10 2021-2022
Philips North America LLC $101.91 2019
Gilead Sciences, INC. $79.77 2019-2022
Allergan, INC. $62.35 2019-2020
Tetraphase Pharmaceuticals, INC. $44.29 2019-2020
Viiv Healthcare Company $37.14 2020-2022
Amgen INC. $27.36 2021-2022
Napo Pharmaceuticals INC $22.92 2020
Lilly USA, LLC $22.28 2022
Janssen Pharmaceuticals, INC $20.25 2021
Show all 20 companies
CompanyGeneral paymentsYearsTop products
Alexion Pharmaceuticals, INC. $19.89 2022
Theratechnologies INC. $19.86 2019
Mayne Pharma Commercial LLC $17.56 2020
Pfizer INC. $14.91 2021
Cumberland Pharmaceuticals, INC. $11.75 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Sushma Singh

$1,596.18

in general payments reported 2019-2025

Years
2019-2022
Top company
Merck Sharp & Dohme LLC

https://glasscript.com/doctor/1082076/sushma-singh

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Download CSV

The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.